Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 2/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19206327 | 0.98 | METAP2 (0.33) | METAP2METAP1SIGMAR1DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL19206340 | 0.97 | METAP2 (0.33) | METAP2METAP1SIGMAR1DRD2DRD4 | |
| SCHEMBL19206351 | 0.93 | — | — | |
| SCHEMBL19206349 | 0.92 | METAP2 (0.31) | METAP2METAP1 | |
| SCHEMBL19206336 | 0.90 | — | — | |
| SCHEMBL19206408 | 0.89 | — | — | |
| SCHEMBL16935201 | 0.84 | SIGMAR1 (0.38) | SIGMAR1DRD2DRD4 | |
| SCHEMBL19206432 | 0.84 | — | — | |
| SCHEMBL19206373 | 0.83 | DRD2 (0.35) | DRD2DRD4 | |
| SCHEMBL19206345 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10072033-B2 | N-(phosphinoalkyl)-N-(thioalkyl)amine derivative, method for producing same, and metal complex thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-09-11 | — | — | US | disclosed |
| US-20170233418-A1 | N-(PHOSPHINOALKYL)-N-(THIOALKYL)AMINE DERIVATIVE, METHOD FOR PRODUCING SAME, AND METAL COMPLEX THEREOF | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233418-A1 | N-(PHOSPHINOALKYL)-N-(THIOALKYL)AMINE DERIVATIVE, METHOD FOR PRODUCING SAME, AND METAL COMPLEX THEREOF | NSFL1C, TST, NCL | METAP2 1164/4885METAP1 737/4885SIGMAR1 1048/4885 |
| US-10072033-B2 | N-(phosphinoalkyl)-N-(thioalkyl)amine derivative, method for producing same, and metal complex thereof | NSFL1C, TST, NCL | METAP2 1164/4885METAP1 737/4885SIGMAR1 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.